

REVIEW

A Review of Hemp As Food and Nutritional Supplement

Pellegrino Cerino,^{1–4} Carlo Buonerba,^{1,2,5,*} Giuseppe Cannazza,^{6,7} Jacopo D’Auria,^{1,2} Ermete Ottoni,^{1,2} Andrea Fulgione,¹ Antonio Di Stasio,^{1,2} Biancamaria Pierri,^{1,2,8} and Alfonso Gallo^{1,2}

Abstract

The term “hemp” refers to *Cannabis sativa* cultivars grown for industrial purposes that are characterized by lower levels of tetrahydrocannabinol (THC), the active principle responsible for *Cannabis* psychotropic effects. Hemp is an extraordinary crop, with enormous social and economic value, since it can be used to produce food, textiles, clothing, biodegradable plastics, paper, paint, biofuel, and animal feed, as well as lighting oil. Various parts of the hemp plant represent a valuable source of food and ingredients for nutritional supplements. While hemp inflorescence is rich in nonpsychoactive, yet biologically active cannabinoids, such as cannabidiol (CBD), which exerts potent anxiolytic, spasmolytic, as well as anticonvulsant effects, hempseed has a pleasant nutty taste and represents a valuable source of essential amino acids and fatty acids, minerals, vitamins, and fibers. In addition, hempseed oil is a source of healthy polyunsaturated fatty acids, and hemp sprouts are rich in antioxidants. This review article aims to provide a comprehensive outlook from a multidisciplinary perspective on the scientific evidence supporting hemp beneficial properties when consumed as food or supplement. Marketing of hemp-derived products is subjected to diversified and complex regulations worldwide for several reasons, including the fact that CBD is also the active principal of pharmaceutical agents and that regulatory bodies in some cases ban *Cannabis* inflorescence regardless of its THC content. Some key regulatory aspects of such a complex scenario are also analyzed and discussed in this review article.

Keywords: cannabidiol; cannabinoids; *Cannabis*; hemp food; hemp

Introduction

Cannabis is a genus of flowering plants belonging to the family of Cannabaceae. According to some authors, the *Cannabis* genus includes three different species, such as *Cannabis sativa*, *C. indica*, and *C. ruderalis*.¹ Alternatively, it is considered as monospecific (*Cannabis sativa* L.) with two subspecies [*Cannabis sativa* L. subsp. *sativa* and *Cannabis sativa* L. subsp. *indica* (Lam.) E. Small & Cronq.] and four varieties [*Cannabis sativa* L. subsp. *sativa* var. *sativa*; *Cannabis sativa* L. subsp. *sativa* var. *spontanea* Vavilov; *Cannabis sativa* L. subsp. *indica* (Lam.) E. Small & Cronq. var. *indica*; and *Cannabis sativa* L. subsp. *indica* (Lam.) E. Small & Cronq., var. *kafiristanica* (Vavilov)].² Such a taxonomy was proposed by

Small and Cronquist combining fruit morphology and (–)-trans- Δ^9 -tetrahydrocannabinol (THC) content.² *Cannabis* plants have been used for thousands of years for recreational, medicinal, or religious purposes.³

Currently, there are ~147 million people worldwide who consume *Cannabis*, primarily because of its intoxicating properties mediated by THC.⁴ Most people, who simply have knowledge of *Cannabis* as a recreational drug, ignore the enormous social, industrial, and economic value of “hemp.” Hemp is the term used as opposed to “marijuana” to refer to *Cannabis* varieties characterized by lower THC levels and grown for industrial purposes.⁵ Hemp is a versatile crop, which can be grown at high latitudes⁶ and can

¹National Reference Center for Environmental Health, Zoo-Prophylactic Institute of Southern Italy, Portici, Italy.

²Multidisciplinary Center on Cannabinoid Research—REICA, Zoo-Prophylactic Institute of Southern Italy, Portici, Italy.

³Department of Public Health, “Federico II” University, Naples, Italy.

⁴Epidemiology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Napoli, Italy.

⁵Department of Oncology and Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples, Italy.

⁶Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.

⁷CNR NANOTEC, Campus Ecotekne of the University of Salento, Lecce, Italy.

⁸Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana,” University of Salerno, Baronissi, SA, Italy.

*Address correspondence to: Carlo Buonerba, MD, National Reference Center for Environmental Health, Zoo-Prophylactic Institute of Southern Italy, Via Della Salute, 2, Portici 80055, Italy, E-mail: carbuone@hotmail.com; carlo.buonerba@izsmportici.it; carlo.buonerba@unina.it

be used to produce food, textiles, clothing, biodegradable plastics, paper, paint, biofuel, and animal feed, as well as lighting oil.⁷ In 1938, the Popular Mechanics magazine defined hemp as “the new billion-dollar crop,” with about 30,000 different products derived from the fiber and the stalk of plant.

Over the past decades, to counteract its widespread use as a recreational drug, the authorities had banned cultivation of any variety of *Cannabis* without making a distinction based on the THC content, which severely and unfairly harmed the hemp industry. During the past few years most Western countries have recognized the incontrovertible economic, potential, and social value of industrial hemp and even promoted its cultivation through *ad hoc* legislative interventions, which have established a legal threshold for THC concentration in the dry plant material (e.g., 0.2% in the European Union).⁸ In the United States, hemp is not considered as a controlled substance subject to Drug Enforcement Administration (DEA) regulation and can be produced according to the 2014 farm bill provision, although some aspects are still overseen by DEA, including the importation of viable seeds.⁹

Hempseeds and inflorescence are extensively used worldwide as source of food and supplement ingredients. Hemp inflorescence is rich in nonpsychoactive, yet biologically active cannabinoids, such as cannabidiol (CBD), which exerts potent anxiolytic, spasmolytic, as well as anticonvulsant effects, among others.¹⁰ CBD nutritional supplements account for approximately one-third of the global 1.34 billion dollar market for CBD.¹¹ Hempseed has a pleasant nutty taste and represents a valuable source of essential fatty acids, minerals, vitamins, and fibers, as well as of essential amino acids contained in the highly digestible proteins edestin and albumin.¹² Hempseed oil is composed for its greater part (>90%) of polyunsaturated fatty acids¹³ known for their beneficial effects against cardiovascular diseases, cancer, and inflammatory conditions.^{14,15}

Hemp sprouts can also be consumed as food. Compared to hempseeds, hemp sprouts are characterized by higher content in total polyphenols, flavonoids, and flavonols, known for their positive cardiovascular and metabolic effects.¹⁶ Besides the multiple potential advantages—most of which are yet to be proved in large prospective trials—associated with the hundreds of different compounds found in hemp, dietary consumption of hemp products may also carry potential risks for public health, mostly related to the excessive exposure to psychoactive and nonpsychoactive canna-

binoids, that may be present as undesired contaminants¹⁷ or may be purposely consumed in excessive and potentially harmful amounts. Presently, marketing of CBD-based dietary supplements, which is under intense debate in the scientific community,¹⁸ is differently regulated in the United States, Europe, and the rest of the world.

The aim of this narrative review is to provide a comprehensive analysis of the available scientific evidence on the composition, nutritional properties, as well as safety of hemp consumed as food and nutritional supplements, with a focus on the related complex socioeconomic and regulatory aspects.

Hemp Bioactive Compounds

The extensive research that has probably made *Cannabis* the most studied plant in human history has allowed to identify hundreds of different compounds with potential biological activity, including more than 120 terpenoids, 100 cannabinoids, 50 hydrocarbons, 34 glycosidic compounds, 27 nitrogenous compounds, 25 noncannabinoid phenols, 22 fatty acids, 21 simple acids, 18 amino acids, 13 simple ketones, 13 simple esters and lactones, 12 simple aldehydes, 11 proteins, glycoproteins, and enzymes, 11 steroids, 9 trace elements, 7 simple alcohols, 2 pigments, as well as vitamin K.¹⁹

Two recently published studies using an optimized method for chemical characterization of hemp identified 189 lipids, including 52 phospholipids and 80 sulfolipids,²⁰ and 147 compounds belonging to the classes of flavonoids, proanthocyanidins, and phenolic acids.²¹ Nonpsychoactive cannabinoids reported in hemp include the abovementioned CBD, as well as cannabichromene (CBC), cannabigerol (CBG), cannabinol, cannabicyclol, cannabielsoin, cannabitrinol, and others.²² Part of their biological activity can be explained by the interaction with the endocannabinoid system, which includes two G protein-coupled cannabinoid receptors (CB1 and CB2) and two endogenous ligands (anandamide and 2-arachidonoylglycerol).^{23,24}

The endocannabinoid system is physiologically involved in regulation of appetite, pain, mood, memory, inflammation, insulin sensitivity, as well as fat and energy metabolism, with a wide variety of potential therapeutic implications for treatment of pain, neuropsychiatric disorders, neurological diseases, and inflammatory bowel, which may benefit from CB1 activation, as well as for treatment of obesity, type 2 diabetes, and hepatic or kidney disorders, which may benefit from CB1 antagonism.²⁵

CBD is biosynthesized as a carboxylic acid through the same metabolic pathway as THC, with the exception of the last chemical reaction that is catalyzed by CBD acid synthase instead of THC acid synthase.²⁶ CBD exerts a wide range of biological effects, including anti-convulsant, anxiolytic, anti-inflammatory, immunomodulating, and antineoplastic activity, as shown in multiple pre-clinical models. CBD dose-dependent anti-convulsant activity was also shown in a 4-aminopyridine model prepared using mouse hippocampal brain slices at concentrations ranging from 0.01 to 100 μM , as well as *in vivo* in a pentylenetetrazole model of generalized seizures, at doses of 1, 10, and 100 mg/kg.^{27,28}

A potent anxiolytic effect of CBD has also been shown in pre-clinical models. In mice undergoing 2 weeks of chronic unpredictable stress, CBD repeated administration at the dose of 30 mg/kg exerted a potent anxiolytic effect through the CB1 cannabinoid receptor, as suggested by evidence of higher hippocampal anandamide levels associated with CBD administration and reversal of CBD effects through administration of a CB1-selective antagonist.²⁹

Interestingly, CBD spectrum of biological activities includes immune-modulating and anti-inflammatory properties. In a mouse paw model of acute carrageenan-mediated inflammation, oral daily administration of CBD at doses ranging from 5 to 40 mg/kg for 3 days was able to reduce edema, prostaglandin E2 plasma levels, tissue cyclooxygenase activity, production of oxygen-derived free radicals, and nitric oxide after three doses of CBD.³⁰ Anti-inflammatory effects may be explained by inverse agonism activity toward the CB2 receptor,³¹ which inhibits immune cell migration both in macrophages³² and human neutrophils.³³ CBD may also exert potent and specific activity against neuroinflammation processes, which are involved in a number of neurodegenerative disorders.³⁴

In an experimental murine multiple sclerosis model obtained through inducing autoimmune encephalomyelitis through immunization with myelin oligodendrocyte glycoprotein, CBD (5 mg/kg) administered for 3 days–3 weeks after myelin antigen administration at the time of disease onset was able to slow progression and reduce severity of the autoimmune encephalomyelitis. Clinical activity was accompanied by histologic evidence of diminished axonal damage and microglial activation and by *in vitro* evidence of decreased T cell proliferation in response to the myelin antigen.³⁵

CBD also presents antineoplastic activity shown in several pre-clinical models. Among five different can-

nabinoids, including CBD, CBG, CBC, cannabidiol acid, and THC acid, CBD exhibited the strongest *in-vitro* antineoplastic activity in a panel of different cancer cell types, with an IC(50) between 6.0 and 10.6 μM .³⁶ The underlying mechanism of action may be mediated by CBD-induced production of reactive oxygen species and desensitization of transient receptor potential cation channel, subfamily A, member 1 (TRPA1),³⁶ which plays a critical role in maintaining cellular homeostasis in response to oxidative stress.³⁷

TRPA1 is also desensitized by the strong agonistic activity exerted by another cannabinoid lacking psychotropic effects, CBC, which results in a potent anti-inflammatory effect, as shown in a mouse model of colitis induced by dinitrobenzene sulfonic acid.³⁸ CBG has also proven to reduce inflammation in an experimental murine model of colitis.³⁹ CBG may also reduce intraocular pressure, as shown after chronic topical administration to the eyes of cats.⁴⁰

Terpenes found in hemp, which confer the typical aroma and flavor, may also exert multiple biologically relevant effects. β -Myrcene and limonene are among the most abundant terpenes in hemp. In a mouse model of osteoarthritis, myrcene showed meaningful anti-inflammatory activity in human chondrocytes.⁴¹ *In vitro* studies also suggest that β -myrcene may be useful to treat pain through interaction with transient receptor potential cation channel subfamily V member 1 (TRPV1) channels.⁴² Limonene may exert antiallergic activity.

In an *in vitro* study conducted in human eosinophilic leukemia HL-60 clone 15 cells, limonene was capable of inhibiting reactive oxygen species production even at low concentrations (7.34 mmol/L), while at 14.68 mmol/L concentration limonene was able to decrease monocyte chemotactic protein-1 (MCP-1) synthesis, which suggests a potential clinical action against bronchial asthma,⁴³ as also confirmed by reduced allergic airway inflammation obtained with limonene inhalation in an experimental mouse model.⁴⁴ Another terpene found in hemp, β -Caryophyllene, has shown potent anxiolytic effects in mice.⁴⁵ Finally, cannaflavin A and B are two flavones with potent antioxidant activity found in hemp inflorescence that have shown to reduce prostaglandin E2 synthesis in cultures of human rheumatoid synovial cells⁴⁶ and may therefore provide anti-inflammatory effects in humans.⁴⁷

Hemp Supplements

As a plant-derived, easily extractable, biologically active compound with large therapeutic index and

overall excellent safety profile, CBD is currently marketed both as a mainly hemp-derived dietary supplement, subjected to evolving legislation and regulatory actions, and as a drug, such as Epidiolex (CBD only) and Sativex (THC and CBD in 1:1 ratio), with specific approval indications worldwide.

Epidiolex is currently both European Medical Agency- and Food and Drug Administration approved against seizures associated with Lennox–Gastaut or Dravet syndrome in patients 2 years of age or older on the grounds of high quality scientific evidence from randomized controlled trials.^{48,49} Concordantly with its biological activity discussed above and demonstrated in pre-clinical models, accumulating evidence from clinical trials suggests that CBD as a pharmaceutical agent has the potential to gain a number of additional indications for the treatment of sleep disorders, social phobia, post-traumatic stress syndrome, substance abuse and dependence, schizophrenia, bipolar disorder, depression, and Parkinson's disease.⁵⁰

While CBD has been administered up to 6000 mg/day in phase I studies,⁵¹ Epidiolex recommended that starting dose for the approved indications is 5 mg/kg, which can be increased up to 20 mg/kg/day.⁵² Compared to placebo, Epidiolex has shown dose-dependent increased incidence of alanine aminotransferase elevations above thrice the upper limit of normal (13% vs. 1%, mainly in patients treated at the 20 mg/kg daily dose).⁵² Dose-dependent CBD potential for inducing liver toxicity when administered at pharmacological doses is confirmed by pre-clinical experiences in the mouse model.⁵³

In Epidiolex registrative trials, somnolence and sedation were reported in 34% and 27% of patients consuming 20 versus 10 mg/kg/day, while the risk of suicidal behavior associated with Epidiolex versus placebo was ~3.5 fold.⁴⁸ Decreased appetite, fatigue, diarrhea, transaminase elevation, rash, sleep disorders, as well as infections, were also reported in >10% of subjects treated with Epidiolex.⁴⁸ In view of the variety of potentially life-threatening adverse events, as well as of the recommended precautions and warnings, besides potential drug–drug interactions reported with CBD at pharmacological doses, the FDA has prohibited marketing of CBD as an ingredient for nutritional supplements,¹⁸ which appears in contradiction with United States federal court ruling establishing that hemp-derived products, including those containing CBD, could be freely marketed under the 2014 Farm Bill.⁵⁴

The scenario is also confusing in Europe, where CBD-containing products (e.g., CBD-enriched hemp oil) have

been classified as novel foods because their use was not widespread in Europe before 1997,⁵⁵ which makes it mandatory to apply for authorization to place dietary CBD products on the market. One application requesting CBD to be authorized as a novel food with a daily intake of up to 130 mg or 1.86 mg/kg body weight has been filed by Cannabis Pharma, s.r.o. (Czech Republic) and remains currently pending.⁵⁶

Despite such a regulatory and legislative confusion, the importance of the CBD issue from a public health perspective lies in its widespread self-administration without any medical supervision and wide availability as a supplement, with a market worth for retail sales of hemp-derived CBD products of \$170 million in 2016 in the United States alone and a projected market worth of hemp-derived CBD of \$22 billion in 2022.⁵⁷ Furthermore, in view of the lack of stringent controls of marketed products by the competent authorities, mislabeling of CBD supplements is frequent, which may represent a fraud for consumers, as well as pose a risk for their health.

In a study involving 88 CBD liquid products, including oil and vaporization liquid, marketed by 31 different companies, CBD median levels were 9.45 mg/mL (range 0.10–655.27 mg/mL), which was lower compared to the median labeled concentration of 15.00 mg/mL (range 1.33–800.00). CBD-containing oil to be consumed orally was inaccurately labeled in 55% of cases.⁵⁸ The FDA has sent warning letters to several companies requesting them to stop claiming that their CBD products may treat or even cure serious diseases, including cancer.⁵⁹

The widespread use of CBD products has been poorly investigated. One study recruited 2409 individuals who participated in an online survey designed to assess the reasons, risks, and modalities behind CBD consumption.⁶⁰ Approximately a third of participants reported some nonserious adverse event, with the most frequently occurring adverse events being dry mouth (11.12%), euphoria (6.43%), hunger (6.35%), red eyes (2.74%), and sedation/fatigue (1.78%). Among the 1483 users who reported using CBD to treat a medical condition, which most frequently included pain, anxiety, depression, and sleep disorders, approximately one-third of participants stated that CBD alone could manage their medical condition by itself.

Importantly, ~40% of participants were motivated to consume CBD as part of a healthy lifestyle. Despite its numerous limitations, including the lack of data

regarding the dose consumed and timing of consumption, as well as the absence of a control group, this study has the merit to capture consumers' motivations behind CBD use, which is essential to direct further research and investigations, as well as regulatory interventions.

Despite the large consumption of CBD as a nutritional supplement, evidence from pre-clinical and clinical studies exploring the effects of CBD as a dietary ingredient is scarce to nonexistent. In one pre-clinical study conducted in eight dogs and eight cats,⁶¹ CBD administered at the daily dose of 4 mg/kg for 12 weeks did not cause any alteration in complete blood count or serum chemistry, with the exception of one cat showing persistent abnormalities in alanine aminotransferase levels. Dogs presented few adverse events, including loose stool and vomiting occurring for <5% of the observation time, while cats showed multiple adverse events, including licking and head shaking, observed for 35.4% and 25.2% of the observation time, respectively.

In a small interventional prospective trial, including 12 individuals receiving up to 90 mg of single oral doses of CBD and assessed for cardiovascular and cognitive functions after CBD consumption, increased cerebral perfusion and reduced blood pressure compared with baseline were reported in a subgroup of participants receiving 90 mg CBD, without any clinically evident adverse events or laboratory alteration in blood count, inflammation, or metabolic markers.⁶²

Although adequate trials assessing CBD effects when administered as nutritional supplement in large populations and for a prolonged period of time are lacking, the clinical evidence summarized here allows to hypothesize that the acceptable dose for supplementation in adults may be comprised between the total dose of 5–10 mg/day, obtained by roughly estimating CBD exposure through historic use patterns based on the available data on smoked *Cannabis*⁶³ and the pharmacological total daily doses >350 mg a day, that is, in the range of 50–100 mg a day. This may represent the dose range for testing CBD hemp supplements as part of a healthy diet.

The need for further research is becoming more compelling as multinational companies such as Coca-Cola are planning to supplement some of their products with CBD,⁶⁴ which will expand the variety of CBD-supplemented food and beverages—as an example, a Californian company is marketing CBD-supplemented wine,⁶⁵ while New York-based company

Sovereign Vines has produced a wine with special tastes and flavors of hemp.

Hemp Food

Hemp has been a valuable source of food for mankind for millennia, as shown by the hempseeds found in tombs dating back to the third millennium before Christ in China, where roasted hempseed can still be bought on the street as snacks.⁶⁶ Although hemp leaves, sprouts, and flowers can be consumed as a raw food by preparing juices and salads,⁶⁷ hempseeds represent the most common part of the hemp plant to be consumed as food. The true seed is an achene, enveloped by a subtle and hard pericarp, and matures 3–6 weeks after the fertilization of female flower.⁶⁸ Hempseeds provide ~500–600 Kcal/100 g of product and are composed of approximately one-fourth of proteins, one-fourth of carbohydrates, and one-third of fat,⁶⁹ with some significant variations among different genotypes.⁷⁰

Hempseeds are rich in polyunsaturated fatty acids, which also vary among different genotypes. One study of seven different hempseed cultivars (“Bialobrzekie,” “Felina 32,” “Tygra 75,” “Futura 27,” “Santhica,” “Fedora 17,” and “Finola”) showed that “Finola” had the highest content of γ linolenic and α -linolenic acids and the lowest content in oleic acid and saturated fatty acids, such as palmitic and stearic acids.⁷⁰

Hempseed proteins represent a valuable source of sulfur-containing amino acid methionine and cystine and provide high quantities of arginine, an essential amino acid with beneficial cardiovascular properties. Accumulating evidence supporting the antihypertensive effect of hydrolyzed hempseed proteins, possibly mediated by inhibition of angiotensin-converting enzyme and renin,⁷¹ provided the rationale for an ongoing human trial testing hemp protein powder as an antihypertensive nutritional intervention.⁷²

This trial is going to enroll 35 individuals showing systolic blood pressure >130 mmHg or elevated diastolic blood pressure \leq 110 mmHg, who will be randomized to a dietary intervention consisting of either 25 g of casein or 25 g of hempseed protein or 22.5 g of hempseed protein added with 2.5 g of hempseed protein hydrolysate derived enriched with bioactive peptides.⁷² Finally, as little as 50 mg of hempseeds can cover 50–100% of the recommended daily intake of several minerals, including copper, magnesium, and zinc, and provide >100% of the daily recommended dose of vitamins A, D, and E.⁷³

Hempseeds can also be used to make flour and oil with valuable nutritional properties. In one study, flour of hemp “Fedora” contains moisture, protein, lipids, carbohydrates, and ash in the proportion of 7.9 ± 0.9 , 30.7 ± 1.2 , 13.6 ± 1.9 , 41.6 ± 2.5 , and $6.2 \pm 0.5\%$, respectively, with a high content of total polyphenols quantified with the Folin–Ciocalteu method (744 ± 29 gallic acid equivalents).⁷⁴ Up to 10% of flour obtained from hempseed added to wheat flour did not affect dough stability and dough strength, but improved the nutritional value of the final product by increasing the levels of proteins and minerals.⁷⁵ In another study, the addition of hemp flour to starch to make gluten-free bread was associated with improvement in palatability in terms of flavor and color, as well as in the nutritional value, with increased levels of fibers and proteins.⁷⁶ Crackers made from hemp flour have also improved nutritional value.⁷⁷

Hempseed oil is the most commonly used edible hemp derivative, with potential uses also in the cosmetic industry as a sun cream due to its capacity to absorb UV rays and its high content in vitamin E (100 mg/100 mL).⁷⁸ Hempseed oil consists of >80% unsaturated fats with an established cardioprotective effect such as linoleic acid (18:2 omega-6) and α -linolenic acid (18:3 omega-3), which are found in hemp oil at an optimal ratio of 2/3:1.^{74,79} Of note, despite the nutritional value of a balanced content in omega-6:omega-3 fatty acids, most commercially available cooking oils are selected to have a low content in omega-3 fatty acids to improve their stability, as omega-3 fatty acids rapidly turn rancid because of the presence of three double bonds.⁸⁰

In one study evaluating the composition of hempseed oil derived from seven cultivars, including “Novosadska,” “Secuieni,” “Beniko,” “Felina 34,” “Futura 75,” “Tiborszálási,” and “Carmagnola Seleccionata,” the total amount of unsaturated fatty acids was 82–86%, with 51.9–55.7% of linoleic acid and 12.3–15.3% of α -linolenic acid, while γ -linolenic acid, which is involved in inflammatory processes,⁸¹ ranged from 0.8% in domestic “Novosadska” cultivar to 2.46% in “Beniko.”⁸² Hempseed oil also has a high antioxidant capacity due to its content in phenols and flavonoids, with 267.5 ± 8.84 mg of gallic acid equivalents and $2780.4 \text{ mg} \pm 133.06$ of quercetin equivalents in 100 g of fresh cold-pressed hempseed oil from “Finola” cultivar,⁸³ while β -caryophyllene and myrcene have been found at concentrations of 740 and 160 mg/L, respectively.⁸⁴

With its pleasant, nutty-favored taste, with somewhat of a bitter aftertaste,⁸⁵ hempseed oil may be used in cooking as a replacement for olive oil, which has established benefits for cardiovascular health.⁸⁶ Small quantities of hempseed oil (2 g/day) did not produce any effect in plasma levels of total cholesterol, high and low density cholesterol, triglycerides, nor did it induce any effect in terms of platelet aggregation and levels of circulating inflammatory markers in a trial⁸⁷ in a 12-week trial, including 86 healthy participants. These results were confirmed in another trial enrolling 36 children with primary hyperlipidemia, who did not show any improvement in their lipid profile after consuming 3 g of hempseed oil.⁸⁸

Interestingly, daily consumption of 30 mL hempseed versus flaxseed oil was associated with an improvement in the total cholesterol to high density lipoprotein cholesterol ratio⁸⁹ in another small trial enrolling 14 individuals. In another controlled, randomized single-blind crossover study, 20 participants with atopic dermatitis were instructed to consume 30 mL of olive versus hempseed oil during a 20 week period. Importantly, consumption of hempseed oil resulted in subjective decreases in both skin dryness and itchiness along with reduced use of topical medications, while this effect was not reported for olive oil. Although limited, these results suggest that hempseed oil can be part of a diet with potential health advantages. Finally, hemp sprouts may also represent an attractive functional food due to their content in flavonoids and flavanols,⁹⁰ although clinical trials exploring palatability and potential benefits associated with their consumption are lacking.

Future Directions

Hemp potential as an extraordinary source of supplement ingredients and a healthy food remains largely to be investigated in adequately powered clinical trials. FDA position to consider hemp-derived CBD as a drug only with prohibition to market it as a supplement appears as a legitimate safeguard against uncontrolled use of an active principal approved as a drug, which carries the risk of serious adverse events, drug–drug interaction, and cannot and should not be used without medical supervision.

Nevertheless, we believe that CBD is likely to be safely consumed as a nutritional supplement up to a dose of 1–2 mg/kg, as also reported in the position paper by European Industrial Hemp Association.⁹¹ Unfortunately, while data regarding the effects associated with very high doses of CBD (up to 6000 mg/day)

for short periods,⁵¹ data obtained in population studies with a double-blind design and with sufficient power to capture even infrequent adverse effects are currently lacking unfortunately.

Regulatory agencies are allowed to err on the side of prudence provided that sufficient impulse is given to the design and conduction of such clinical studies. Prohibition of CBD marketing as a supplement ingredient within certain dose limits may limit consumers' right to have access to a naturally occurring substance obtained from THC-free hemp, which can be freely marketed. In contrast, interventions aimed at guaranteeing hemp-derived food safety are compulsory. After analyzing the cannabinoid profile by a liquid chromatography method coupled to high-resolution mass spectrometry in 10 commercially available organic hempseed oils, Citti et al.⁹² reported noninsignificant concentrations of THC and CBD besides other 30 cannabinoids, which is probably due to contamination of seeds with inflorescence, as cannabinoids are not found in hempseeds.

The Zoo-Prophylactic Institute of Southern Italy (IZSM) is the first public Italian Institution operating under the supervision of the Italian Ministry of Health and with jurisdiction over food safety to provide assessment of THC content in food and hemp products in Accredia-certified internal laboratories, with enormous implications for public health and hemp law enforcement (www.reica.org). A large, IZSM-sponsored observational study, the HEMPEDOCLE study, is going to recruit ~900 Cannabis users, including 600 individuals who consume hemp-derived *Cannabis* products as food or supplement. This trial is going to prove or disprove safety of dietary hemp products and measure subsequent cannabinoid exposure in participating subjects.

Conclusions

Hemp use in the food and supplement industry is predicted to expand in the coming years as demand grows, with enormous social, economic, and sanitary implications. Legislative and regulatory interventions should aim at encouraging adequate clinical research to prove or disprove safety of hemp-derived products, which has not been done so far independently by the industry or by the scientific community.

Authors' Contributions

P.C., C.B., G.C., and A.G. drafted the article. All authors equally contributed to literature search and critical revision for important intellectual content and finally approved the article.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

No funding was received for this article.

References

1. Pollio A. The name of *Cannabis*: a short guide for nonbotanists. *Cannabis Cannabinoid Res.* 2016;1:234–238.
2. Small E, Cronquist A. A practical and natural taxonomy for *Cannabis*. *Taxon* 1976;25:405–435.
3. Pertwee R. *Handbook of Cannabis*. Oxford, United Kingdom: Oxford University Press, 2014.
4. World Health Organization. *Cannabis*. 2019. Available at https://who.int/substance_abuse/facts/cannabis/en/ Accessed November 30, 2019.
5. Cadena A. Hemp vs marijuana: the difference explained (2019 update). 2018. Available at <https://medium.com/cbd-origin/hemp-vs-marijuana-the-difference-explained-a837c51aa8f7> Accessed November 30, 2019.
6. Callaway JC. Hemp as food at high latitudes. *J Ind Hemp* 2002;7:105–117.
7. Ranalli P, Venturi G. Hemp as a raw material for industrial applications. *Euphytica* 2004;140:1–6.
8. Italian Parliament. Rule 2 December 2016, article n. 242: Provisions for the promotion of the cultivation and agro-industrial supply chain of hemp (in Italian). 2016; pp. 1–6
9. Johnson R. Hemp as an agricultural commodity. Congressional Research Service 7-5700. 2018. Available at <https://fas.org/sgp/crs/misc/RL32725.pdf> Accessed November 30, 2019.
10. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. *J Clin Pharmacol.* 2002;42:115–195.
11. Grand View Research. Cannabidiol market size, share and trends analysis report by source (hemp, marijuana), by application, by distribution channel, by region, and segment forecasts, 2019–2025. 2019. Available at <https://grandviewresearch.com/industry-analysis/cannabidiol-cbd-market> Accessed October 30, 2019.
12. Callaway JC. Hempseed as a nutritional resource: an overview. *Euphytica* 2004;140:65–72.
13. Chen T, He J, Zhang J, et al. Analytical characterization of hempseed (seed of *Cannabis sativa* L.) oil from eight regions in China. *J Diet Suppl.* 2010;7: 117–129.
14. Roche HM. Unsaturated fatty acids. *Proc Nutr Soc.* 1999;58:397–401.
15. Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance—a review. *Life Sci.* 2018; 203:255–267.
16. Menezes R, Rodriguez-Mateos A, Kaltsatou A, et al. Impact of flavonols on cardiometabolic biomarkers: a meta-analysis of randomized controlled human trials to explore the role of inter-individual variability. *Nutrients* 2017;9:E117.
17. Citti C, Pacchetti B, Vandelli MA, et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). *J Pharm Biomed Anal.* 2018;149:532–540.
18. Cohen PA, Sharfstein J. The opportunity of CBD—reforming the law. *N Engl J Med.* 2019;381:297–299.
19. Hazekamp A, Fishedick JT, Díez ML, et al. *Chemistry of Cannabis*. In: Mander L, Lui H-W. (eds.) *Comprehensive natural products II chemistry biology*, Vol. 3. Elsevier: Oxford, United Kingdom, 2010, pp. 1033–1084.
20. Antonelli M, Benedetti B, Cannazza G, et al. New insights in hemp chemical composition: a comprehensive polar lipidome characterization by combining solid phase enrichment, high-resolution mass spectrometry, and cheminformatics. *Anal Bioanal Chem.* 2019;412:423–423.
21. Cerrato A, Cannazza G, Capriotti A, et al. A new software-assisted analytical workflow based on high-resolution mass spectrometry for the systematic study of phenolic compounds in complex matrices. *Talanta* 2020;209:120573.
22. Hartsel JA, Eades J, Hickory B, et al. *Cannabis sativa* and hemp. In: Gupta RC, Srivastava A, Lall R. (eds.) *Nutraceuticals in Veterinary Medicine*. Springer: Basel, Switzerland, 2019, pp. 735–754.
23. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched *Cannabis* extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol.* 2011;163:1479–1494.

24. Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. *Neurotherapeutics* 2015;12:692–698.
25. Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. *Nat Rev Drug Discov*. 2018;17:623–639.
26. Laverty KU, Stout JM, Sullivan MJ, et al. A physical and genetic map of *Cannabis sativa* identifies extensive rearrangements at the THC/CBD acid synthase loci. *Genome Res*. 2019;29:146–156.
27. Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. *J Pharmacol Exp Ther*. 2010;332:569–577.
28. Sun Y, Dolmetsch RE. Erratum: investigating the therapeutic mechanism of cannabidiol in a human induced pluripotent stem cell (iPSC)-based model of Dravet syndrome. *Cold Spring Harb Symp Quant Biol*. 2018;83:038919.
29. Campos AC, Ortega Z, Palazuelos J, et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. *Int J Neuropsychopharmacol*. 2013;16:1407–1419.
30. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of *cannabis*, in acute carrageenan-induced inflammation in the rat paw. *Naunyn Schmiedeberg Arch Pharmacol*. 2004;369:294–299.
31. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol*. 2008;153:199–215.
32. Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. *J Neurosci*. 2003;23:1398–1405.
33. McHugh D, Tanner C, Mechoulam R, et al. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. *Mol Pharmacol*. 2008;73:441–450.
34. Poupot R, Bergozza D, Fruchon S. Nanoparticle-based strategies to treat neuro-inflammation. *Materials (Basel)* 2018;11:pii:E270.
35. Kozela E, Lev N, Kaushansky N, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. *Br J Pharmacol*. 2011;163:1507–1519.
36. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther*. 2006;318:1375–1387.
37. Takahashi N, Chen HY, Harris IS, et al. Cancer cells co-opt the neuronal redox-sensing channel *trpa1* to promote oxidative-stress tolerance. *Cancer Cell* 2018;33:985–1003.e7.
38. Romano B, Borrelli F, Fasolino I, et al. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. *Br J Pharmacol*. 2013;169:213–229.
39. Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychoactive plant cannabinoid cannabigerol on experimental inflammatory bowel disease. *Biochem Pharmacol*. 2013;85:1306–1316.
40. Colasanti BK. A comparison of the ocular and central effects of δ 9-tetrahydrocannabinol and cannabigerol. *J Ocul Pharmacol*. 1990;6:259–269.
41. Rufino AT, Ribeiro M, Sousa C, et al. Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. *Eur J Pharmacol*. 2015;750:141–150.
42. Jansen C, Shimoda LM, Kawakami JK, et al. Myrcene and terpene regulation of TRPV1. *Channels (Austin)* 2019;13:344–366.
43. Hirota R, Roger NN, Nakamura H, et al. Anti-inflammatory effects of limonene from Yuzu (*Citrus junos* Tanaka) essential oil on eosinophils. *J Food Sci*. 2010;75:H87–H92.
44. Hirota R, Nakamura H, Bhatti SA, et al. Limonene inhalation reduces allergic airway inflammation in *Dermatophagoides farinae*-treated mice. *Inhal Toxicol*. 2012;24:373–381.
45. Bahi A, Al Mansouri S, Al Memari E, et al. β -caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. *Physiol Behav*. 2014;135:119–124.
46. Barrett ML, Scutt AM, Evans FJ. Cannflavin A and B, prenylated flavones from *Cannabis sativa* L. *Experientia* 1986;42:452–453.
47. Werz O, Seegers J, Schaible AM, et al. Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. *PharmaNutrition* 2014;2:53–60.
48. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *N Engl J Med*. 2017;376:2011–2020.
49. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2018;391:1085–1096.
50. Crippa JA, Guimarães FS, Campos AC, et al. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. *Front Immunol*. 2018;9:2009.
51. Taylor L, Gidal B, Blakey G, et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. *CNS Drugs* 2018;32:1053–1067.
52. EPIDIOLX[®]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2103651bl.pdf Accessed November 3, 2019.
53. Ewing EL, Skinner MC, Quick MC, et al. Hepatotoxicity of a cannabidiol-rich *Cannabis* extract in the mouse model. *Molecules* 2019;24:pii:E1694.
54. Kight R. The HIA v. DEA ruling and a Wisconsin policy underline need for clarity on CBD. 2018. Available at <https://cannabusiness.law/a-tough-week-for-cbd-the-hia-v-dea-ruling-and-a-wisconsin-policy-underline-need-for-clarity/> Accessed November 3, 2019.
55. European Commission. EU novel food catalogue (v.1.1). 2019. Available at http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm Accessed November 20, 2019.
56. Cannabis Pharma. Summary of the dossier: (–)-trans-cannabidiol applicant. 2019. Available at https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_sum_ongoing-app_2018-0349.pdf Accessed November 30, 2019.
57. The Brightfield Team. Hemp-derived CBD market to reach \$22 billion by 2022. 2019. Available at <https://brightfieldgroup.com/post/hemp-cbd-market-to-reach-22-billion-by-2022> Accessed November 3, 2019.
58. Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling accuracy of cannabidiol extracts sold online. *JAMA* 2017;318:1708–1709.
59. Corroon J, Kight R. Regulatory status of cannabidiol in the United States: a perspective. *Cannabis Cannabinoid Res*. 2018;3:190–194.
60. Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. *Cannabis Cannabinoid Res*. 2018;3:152–161.
61. Deabold AK, Schwark SW, Wolf L, et al. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. *Animals (Basel)* 2019;9:pii:E832.
62. Patrician A, Versic-Bratinčević M, Mijacika T, et al. Examination of a new delivery approach for oral cannabidiol in healthy subjects: a randomized, double-blinded, placebo-controlled pharmacokinetics study. *Adv Ther*. 2019;36:3196–3210.
63. Cogan PS. On healthcare by popular appeal: critical assessment of benefit and risk in cannabidiol based dietary supplements. *Expert Rev Clin Pharmacol*. 2019;12:501–511.
64. Skerritt J and Giammona C. Coca-Cola, Aurora Cannabis in talks about CBD oil soda – Bloomberg. 2018. Available at <https://www.bloomberg.com/news/articles/2018-09-17/coca-cola-eyes-cannabis-market-in-push-beyond-sluggish-sodas> Accessed November 30, 2019.
65. Barrons C. 4 cannabis-infused wines worth buying. 2018. Available at <https://www.bloomberg.com/news/articles/2018-09-17/coca-cola-eyes-cannabis-market-in-push-beyond-sluggish-sodas> Accessed November 30, 2019.
66. Li HL. The origin and use of *Cannabis* in eastern Asia linguistic-cultural implications. *Econ Bot*. 1974;28:293–301.
67. Royal Queen Seeds. The therapeutic and dietary benefits of eating raw *Cannabis*. 2017. Available at <https://www.royalqueenseeds.com/blog-the-therapeutic-and-dietary-benefits-of-eating-raw-cannabis-n517> Accessed November 30, 2019.
68. Chandra S, Lata H, ElSohly MA. *Cannabis sativa* L.—botany and biotechnology. New York: Springer, 2017.
69. Rodriguez-Leyva D, Pierce GN. The cardiac and haemostatic effects of dietary hempseed. *Nutr Metab (Lond)*. 2010;7:32.
70. Irakli M, Tsaliki E, Kalivas A, et al. Effect of genotype and growing year on the nutritional, phytochemical, and antioxidant properties of industrial hemp (*Cannabis sativa* L.) seeds. *Antioxidants (Basel)* 2019;8:pii:E491.
71. Aluko RE. Hemp seed (*Cannabis sativa* L.) proteins: composition, structure, enzymatic modification, and functional or bioactive properties. *Sustainable Protein Sources*. Cambridge, MA: Academic Press, 2017, pp. 121–132.

72. University of Manitoba. Hemp seed protein consumption for hypertension. 2019. Available at <https://clinicaltrials.gov/ct2/show/NCT03508895> Accessed November 30, 2019.
73. Andrews KW, Gusev PA, McNeal M, et al. Dietary supplement ingredient database (DSID) and the application of analytically based estimates of ingredient amount to intake calculations. *J Nutr.* 2018;148:14135–14215.
74. Siano F, Moccia S, Picariello G, et al. Comparative study of chemical, biochemical characteristic and ATR-FTIR Analysis of seeds, oil and flour of the edible Fedora cultivar hemp (*Cannabis sativa* L.). *Molecules* 2018;24:83.
75. Pojić M, Dapčević Hadnadev T, Hadnadev M, et al. Bread supplementation with hemp seed cake: a by-product of hemp oil processing. *J Food Qual.* 2015;38:431–440.
76. Korus J, Witczak M, Ziobro R, et al. Hemp (*Cannabis sativa* subsp. *sativa*) flour and protein preparation as natural nutrients and structure forming agents in starch based gluten-free bread. *LWT* 2017;84:143–150.
77. Radočaj O, Dimić E, Tsao R. Effects of hemp (*Cannabis sativa* L.) seed oil press-cake and decaffeinated green tea leaves (*Camellia sinensis*) on functional characteristics of gluten-free crackers. *J Food Sci.* 2014;79: C318–C325.
78. Oomah BD, Busson M, Godfrey DV, et al. Characteristics of hemp (*Cannabis sativa* L.) seed oil. *Food Chem.* 2002;76:33–43.
79. Da Porto C, Decorti D, Natolino A. Potential oil yield, fatty acid composition, and oxidation stability of the hempseed oil from four *Cannabis sativa* L. cultivars. *J Diet Suppl.* 2015;12:1–10.
80. Boulouc P. Hemp: industrial production and uses. CAB International: New Delhi, India, 2013.
81. Sergeant S, Rahbar E, Chilton FH. Gamma-linolenic acid, dihomogamma linolenic, eicosanoids and inflammatory processes. *Eur J Pharmacol.* 2016;785:77–86.
82. Dimić E, Romanić R, Vujasinović V. Essential fatty acids, nutritive value and oxidative stability of cold pressed hempseed (*Cannabis sativa* L.) oil from different varieties. *Acta Aliment.* 2009;38:229–236.
83. Smeriglio A, Galati EM, Monforte MT, et al. Polyphenolic compounds and antioxidant activity of cold-pressed seed oil from finola cultivar of *Cannabis sativa* L. *Phytother Res.* 2016;30:1298–1307.
84. Leizer C, Ribnický D, Poulev A, et al. The composition of hemp seed oil and its potential as an important source of nutrition. *J Nutraceut Funct Med Foods* 2000;2:35–53.
85. Matthäus B, Brühl L. Virgin hemp seed oil: an interesting niche product. *Eur J Lipid Sci Technol.* 2008;110:655–661.
86. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med* 2018;378:e34.
87. Kaul N, Kreml R, Austria JA, et al. A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. *J Am Coll Nutr.* 2008;27:51–58.
88. Del Bo C, Deon V, Abello F, et al. Eight-week hempseed oil intervention improves the fatty acid composition of erythrocyte phospholipids and the omega-3 index, but does not affect the lipid profile in children and adolescents with primary hyperlipidemia. *Food Res Int.* 2019;119:469–476.
89. Schwab US, C. Callaway J, Erkkilä AT, et al. Effects of hempseed and flaxseed oils on the profile of serum lipids, serum total and lipoprotein lipid concentrations and haemostatic factors. *Eur J Nutr.* 2006;45: 470–477.
90. Frassinetti S, Moccia E, Caltavuturo L, et al. Nutraceutical potential of hemp (*Cannabis sativa* L.) seeds and sprouts. *Food Chem.* 2018;262:56–66.
91. The European Industrial Hemp Association. Reasonable regulation of cannabidiol (CBD) in food, cosmetics, as herbal natural medicine and as medicinal product. EIHA: Hürth, Germany, 2018.
92. Citti C, Pacchetti B, Vandelli MA, et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). *J Pharm Biomed Anal.* 2018;149:532–540.

Cite this article as: Cerino P, Buonerba C, Cannazza G, D'Auria J, Ottoni E, Fulgione A, Di Stasio A, Pierri B, Gallo A (2021) A review of hemp as food and nutritional supplement, *Cannabis and Cannabinoid Research* 6:1, 19–27, DOI: 10.1089/can.2020.0001.

Abbreviations Used

CBC = cannabichromene
 CBD = cannabidiol
 CBG = cannabigerol
 DEA = Drug Enforcement Administration
 FDA = Food and Drug Administration
 IZSM = The Zoo-prophylactic Institute of Southern Italy
 THC = tetrahydrocannabinol
 TRPA1 = transient receptor potential cation channel, subfamily A, member 1

This article has been cited by:

1. Yue Zhao, Yufeng Sun, Kun Cao, Xiaoyan Zhang, Jing Bian, Chengwei Han, Ying Jiang, Lei Xu, Xiaonan Wang. 2022. Combined use of specific length amplified fragment sequencing (SLAF-seq) and bulked segregant analysis (BSA) for rapid identification of genes influencing fiber content of hemp (*Cannabis sativa* L.). *BMC Plant Biology* **22**:1. . [[Crossref](#)]
2. Rachel A. Burton, Mike Andres, Martin Cole, James M. Cowley, Mary Ann Augustin. 2022. Industrial hemp seed: from the field to value-added food ingredients. *Journal of Cannabis Research* **4**:1. . [[Crossref](#)]
3. Francesco Tolomeo, Fabiana Russo, Dominika Kaczorova, Maria Angela Vandelli, Giuseppe Biagini, Aldo Laganà, Anna Laura Capriotti, Roberta Paris, Flavia Fulvio, Luigi Carbone, Elisabetta Perrone, Giuseppe Gigli, Giuseppe Cannazza, Cinzia Citti. 2022. Cis- Δ 9-tetrahydrocannabinolic acid occurrence in *Cannabis sativa* L. *Journal of Pharmaceutical and Biomedical Analysis* **219**, 114958. [[Crossref](#)]
4. Xinye Liu, Mengzhi Wang, Feng Xue, Benu Adhikari. 2022. Application of ultrasound treatment to improve the technofunctional properties of hemp protein isolate. *Future Foods* **354**, 100176. [[Crossref](#)]
5. Yi Liu, Ai-Ping Xiao, Hao Cheng, Liang-Liang Liu, Kin Weng Kong, Hong-Yan Liu, Ding-Tao Wu, Hua-Bin Li, Ren-You Gan. 2022. Phytochemical differences of hemp (*Cannabis sativa* L.) leaves from different germplasms and their regulatory effects on lipopolysaccharide-induced inflammation in Matin-Darby canine kidney cell lines. *Frontiers in Nutrition* **9**. . [[Crossref](#)]
6. Lidia Montero, Sven W. Meckelmann, Hyerin Kim, Juan F. Ayala-Cabrera, Oliver J. Schmitz. 2022. Differentiation of industrial hemp strains by their cannabinoid and phenolic compounds using LC \times LC-HRMS. *Analytical and Bioanalytical Chemistry* **414**:18, 5445-5459. [[Crossref](#)]
7. Juan F. Garcia, Soledad Arribalzaga, Raquel Diez, Cristina Lopez, M. Nelida Fernandez, Juan J. Garcia, M. Jose Diez, Jesús Seco-Calvo, Matilde Sierra, Ana M. Sahagún. 2022. Herbs as an Active Ingredient in Sport: Availability and Information on the Internet. *Nutrients* **14**:13, 2764. [[Crossref](#)]
8. Rita Ngozi Aguchem, Innocent Uzochukwu Okagu, Ogadimma Desmond Okagu, Joseph Chinedum Ndefo, Chibuikwe C. Udenigwe. 2022. A review on the techno-functional, biological, and health-promoting properties of hempseed-derived proteins and peptides. *Journal of Food Biochemistry* **46**:7. . [[Crossref](#)]
9. Arash Salehi, Keely Puchalski, Yalda Shokoohinia, Behzad Zolfaghari, Sedigheh Asgary. 2022. Differentiating Cannabis Products: Drugs, Food, and Supplements. *Frontiers in Pharmacology* **13**. . [[Crossref](#)]
10. Karolina Barčauskaitė, Renaldas Žydelis, Renaldas Ruzgas, Aušra Bakšinskaitė, Vita Tilvikienė. 2022. The Seeds of Industrial Hemp (*Cannabis Sativa* L.) a Source of Minerals and Biologically Active Compounds. *Journal of Natural Fibers* **19**, 1-15. [[Crossref](#)]
11. Kelly Johnson-Arbor, Susan Smolinske. 2022. The current state of delta-8 THC. *The American Journal of Emergency Medicine* **56**, 259-261. [[Crossref](#)]
12. Iwona Ryłko-Polak, Wojciech Komala, Andrzej Białowiec. 2022. The Reuse of Biomass and Industrial Waste in Biocomposite Construction Materials for Decreasing Natural Resource Use and Mitigating the Environmental Impact of the Construction Industry: A Review. *Materials* **15**:12, 4078. [[Crossref](#)]
13. Sheree J. Finley, Gulnaz T. Javan, Robert L. Green. 2022. Bridging Disciplines: Applications of Forensic Science and Industrial Hemp. *Frontiers in Microbiology* **13**. . [[Crossref](#)]
14. Gonzalo Astray, Juan C. Mejuto, Jianbo Xiao, Jesus Simal-Gandara. 2022. Benefits, toxicity and current market of cannabidiol in edibles. *Critical Reviews in Food Science and Nutrition* **117**, 1-13. [[Crossref](#)]
15. Roberta La Tella, Francesca Rigano, Paolo Guarnaccia, Paola Dugo, Luigi Mondello. 2022. Non-psychoactive cannabinoids identification by linear retention index approach applied to a hand-portable capillary liquid chromatography platform. *Analytical and Bioanalytical Chemistry* **41**. . [[Crossref](#)]
16. Suhred Pathak, Rishi Nadar, Jack Deruiter, Sindhu Ramesh, Jayachandra Babu Ramapuram, Manoj Govindarajulu, Timothy Moore, Dinesh Chandra Agrawal, Muralikrishnan Dhanasekaran. Cannabis as a Unique and Valuable Nutraceutical Formulation for the Current and Future Global Wellbeing 271-299. [[Crossref](#)]
17. Angela Saviano. Cannabis and Organ Damage: A Focus on Pancreatitis (to Include Different Scenarios) 1-11. [[Crossref](#)]
18. Anna Bakowska-Barczak, Yussef Esparza, Harmandeep Kaur, Tomasz Popek. Industrial hemp-based dietary supplements and cosmetic products 247-299. [[Crossref](#)]
19. Hari Prasad Devkota. Hemp (*Cannabis sativa* L.)-Taxonomy, Distribution and Uses 1-10. [[Crossref](#)]
20. Sanusi Shamsudeen Nassarawa, Munir Abba Dandago. Hemp Usage as Regular Food and in Nutraceutical Industry 135-144. [[Crossref](#)]

21. Laura G. A. Esposito, Ezekial Overbaugh, Jia Xiong, Thirumurugan Rathinasabapathy, Slavko Komarnytsky, Derly José Henriques da Silva, Debora A. Esposito. 2021. Immune Responses Are Differentially Regulated by Root, Stem, Leaf, and Flower Extracts of Female and Male CBD Hemp (*Cannabis sativa* L.) Plants. *Immuno* 1:4, 369-379. [[Crossref](#)]
22. Manica Balant, Airy Gras, Mario Ruz, Joan Vallès, Daniel Vitales, Teresa Garnatje. 2021. Traditional uses of Cannabis: An analysis of the CANNUSE database. *Journal of Ethnopharmacology* 279, 114362. [[Crossref](#)]
23. Anna Laura Capriotti, Giuseppe Cannazza, Martina Catani, Chiara Cavaliere, Alberto Cavazzini, Andrea Cerrato, Cinzia Citti, Simona Felletti, Carmela Maria Montone, Susy Piovesana, Aldo Laganà. 2021. Recent applications of mass spectrometry for the characterization of cannabis and hemp phytocannabinoids: From targeted to untargeted analysis. *Journal of Chromatography A* 1655, 462492. [[Crossref](#)]
24. Namsoo Peter Kim, Abhilash Aditya, Hyun-jin Kang, Hee-Deung Park. 2021. Unique Approach of a Telemedicine System for CBD-Infused Foods. *Processes* 9:6, 936. [[Crossref](#)]
25. N. Rol, V. Nadtochiy, A. Tsebro, A. Vovkohon, H. Merzlova, H. Kalinina, O. Hrebelyk. 2021. Hemp raw materials: new perspectives for the food industry. *Tehnologija virobništva i prerobki produktiv tvarinnictva* :1(164), 152-158. [[Crossref](#)]
26. Han Peng, Fereidoon Shahidi. 2021. Cannabis and Cannabis Edibles: A Review. *Journal of Agricultural and Food Chemistry* 69:6, 1751-1774. [[Crossref](#)]
27. Seyed Alireza Salami, Federico Martinelli, Antonio Giovino, Ava Bachari, Neda Arad, Nitin Mantri. 2020. It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets. *Molecules* 25:18, 4036. [[Crossref](#)]
28. H. P. Vasantha Rupasinghe, Amy Davis, Shanthanu K. Kumar, Beth Murray, Valtcho D. Zheljzakov. 2020. Industrial Hemp (*Cannabis sativa* subsp. *sativa*) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals. *Molecules* 25:18, 4078. [[Crossref](#)]